OS Therapies Incorporated OSTX
1.16 USD +0.01 (+0.87%)
At closeNov 3, 2026, 5:14 PM EST
1.15 -0.01 -0.50%
After hours · Nov 3, 5:14 PM ET
1.15 Day range 1.22
1.12 52-week range 2.25
- YTD
- -17.14%
- 1 year
- -37.97%
- Market cap
- 54.29M
- EPS (ttm)
- -1.09
- Shares out
- 21.24M
- Forward P/E
- 2.57
- YTD return
- -17.14%
- 1-year return
- -37.97%
- Volume
- 439.30K
- Avg volume
- 599.30K
- Open
- 1.16
- Previous close
- 1.15
- Day's range
- 1.15 – 1.22
- 52-week range
- 1.12 – 2.25
- Price target
- 12.67 (+992.0%)
1Y -0.63 (-35.39%)
Key statistics
- Enterprise value
- 62.55M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 94.92K
- Total debt
- 16.70M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 2.72
- 200-day average
- 3.11
Analyst view
Price target (mean) 12.67 +992.0% upside
Now 1.16
- Target (low)
- 8.00
- Target (mean)
- 12.67
- Target (high)
- 21.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.14.
Financials — quick view
OSTX Revenue — quarterly 0
OSTX Net income — quarterly -8.63M
OSTX EPS — quarterly -0.20
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 2024 | Maxim Group | init | — | Buy |
| Oct 3, 2024 | EF Hutton | main | Buy | Buy |
| Sep 16, 2024 | EF Hutton | main | Buy | Buy |
| Sep 3, 2024 | EF Hutton | init | — | Buy |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ostherapies.com
News
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million 
Rubenstein Public Relations Named Agency of Record for OS Therapies 
OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma 
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma 
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment 
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment 
OS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical Control 
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial 
OS Therapies Appoints Frank Knuettel II As CFO 
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Your note
Sign in to keep a note on OSTX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Millennium Management Llc | 0.28% | 60,435 | 228.44K | Sep 29, 2024 |
| CM Management, LLC | 0.24% | 50,000 | 189.00K | Sep 29, 2024 |
| Delta Investment Management, LLC | 0.09% | 18,081 | 68.35K | Sep 29, 2024 |
| HRT Financial LP | 0.08% | 17,576 | 66.44K | Sep 29, 2024 |
| Virtu Financial LLC | 0.05% | 10,045 | 37.97K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 3,806 | 14.39K | Sep 29, 2024 |